Lymphoreticular system Flashcards

1
Q

Glucocorticoids

A

Associate with binding proteins - transcortin and albumin
Following dissociation from binding proteins, passively diffuse into cell
Bind to a cytoplasmic receptor (under 3)
Conformational change of receptor unmasks DNA binding domain; associates with GREs following nuclear translocation
Cellular targets:
-Inflammatory cells: eosinophil, T cell, Mast cell, Macrophages, dendritic cell
- Structural cells: epithelium, endothelium, airway smooth muscle, mucus glands

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Glucocorticoid - potential adverse effects

A
Central nervous systen - decreased mentation
Musculoskeletal system - muscle wasting
GIT
Fluid, electrolyte balance
Metabolic, endocrine
immune systems - secondary infections
Cats are more resistance that dogs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Chlorambucil

A

Rapidly metabolised to phenylacetic acid mustard
Slowest acting, least toxic of all alkylating agents
Myelosuppression generally not observed until administered for > 1 month
Urinary and faecal excretion
Administered without food

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Azathioprine

A

Greater decrease of cellular than humoral immunity
Hepatic metabolism to active 6-mercaptopurine then to 6-thioinosinic, 6-thioguanylic, thiouric acids
Compete with endogenous adenine and guanine -> non-functional nucleic acid strands
Slow immunosuppressive effect
Haematological, gastrointestinal, hepatic +/- neuromuscular toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Vincristine, vinblastine

A

Bind to tubulin, blocking polymerisation
Also break down pre-formed microtubules - increased release of PLTs from megakaryocytes
Both used in rxl of ITP (usually vincristine)
Can be given as bolus IV or to preload PLTs
Severe extravascular vesicants
Haematological, GI, neurological toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Ciclosporin

A

Isolated from Cylindrocarpon lucidium and Trichoderma polysporum
Both IV and oral forms
Large volume of distribution: primary hepatic metabolism
Therapeutic drug monitoring - acute and chronic
Ketoconazole may be used to reduce costs
GI, renal, hepatic toxicity; also hirsutism, gingivial hyperplasia, papillomatosis +/- diabetogenic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Pathogenesis of immune-mediated disease

A

Immune system overeacts to normal body tissues or harmless exogenous proteins - loss of tolerance
Both humoral and cellular mechanisms of tissue damage recognied
Loss of self-tolerance is necessary to perpetuate+/- start disease
Trigger factors:
- release of sequestered antigens
- abnormal immunoregulation
- molecular mimicry
- polyclonal activation of T and B cells
- exposure of cryptic epitopes or haptenisation of foreign molecules to self antigens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Role of infection in immune-mediated disease

A
  • Breakdown of vascular or cellular barriers allowing exposure of self antigens
  • Promotion of cell death by necrosis, causing inflammation -> bystander activation
  • Polyclonal activation of T cells - bacterial superantigens
  • Molecular mimicry -> cross reactivity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Aetiology of immune-mediated disease

A

Often unclear, likely to be multifactorial
- Genetic, infectious and hormonal influences
Canine examples:
- SLE: genetics (DLA-A7; C4-4), C-type viruses
- IMHA: vaccinal antigens?
- Immune-mediated polyarthritis: vaccinal antigens?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Signalment of immune-mediated disease

A

Idiopathic immune-mediated disease over-represented in juvenile to middle-aged patients, through dogs and cats of any age may be affected
Vet examples:
- SLE
- Dogs from 2 months - 13y (GSDs, shelties, collies, beagles, poodles)
- Cats from 1-11y (Siamese, Persian, Persian-related breeds)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

History/physical exam of immune-mediated disease

A

Generally characterised by remission and exacerbation
Lameness, mucocutaneous lesions, lethargy, dyspnoea, weight loss, PU/PD, +/- seizures or behavioural changes
Effusive, painful joints, cutaneous erythema, macules, papules, pustules, erosion etc., pallor +/- petechiae, cardiac arrhythmias
Lymphadenomegaly +/- splenomegaly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Diagnostic tests - CBC/coags

Immune-mediated disease

A

Anaemia - regenerative (IMHA) or non-regenerative (infection, uraemia, chronic bleeding, attack of precursors)
Thrombocytopaenia - Immune-mediated (I-M) thrombocytopaenia
Leucopaenia? anti-leucocytes antibodies e.g. SLE, I-M neutropaenia
Coagulation abnormalities: increase in APTT, PT,’anti-coagulant antibody’ (SLE), DIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Diagnostic tests - chemistry panel

Immune-mediated disease

A

Azotaemia, increased inorganic phosphate - chronic glomerular lesions
Hypoalbuminaemia, hypercholesterolaemia - protein-losing nephropathy (PLN)
Hyperbilirubinaemia - pre-hepatic/haemolysis
Hyperglobulinaemia - inflammatory disease, polyclonal B cell activation
Increased creatine kinase and lactate dehydrogenase - polymyositis and/or myocarditis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Diagnostic tests - urinalysis

Immune-mediated disease

A

Proteinuria:
- PLN: r/o UTI and occult infection(s) e.g. Dirofilaria immitis, Ehrlichia canis, Anaplasma phagocytophilum, Borrelia burgdorferi, Rickettsia rickettsiae, Bartonella spp.)
Haematuria, pyuria, erythrocyte casts:
- r/o UTI and occult infections
- compatible with membranoproliferative GN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Diagnostic tests - radiography and arthrocentesis

A

Joint lesions are common in polysystemic IM disease, usually non-erosive pauciarthropathy
Erosive lesions suggest an overlap syndrome
Arthritis is not always clinically obvious
Synovial fluid: increased WBC, increased proportion of neutrophils +/- protein content with decreased viscosity and poor mucin clot formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Coomb’s test

Immune-mediated disease

A

If acute IMHA suspected, in-saline agglutination and osmotic fragility tests may be performed
Antibodies associated with the surface of RBCs may also be detected with the Coomb’s test
Primary reagent: polyvalent anti-dog or anti-cat IgG, IgM and C3 antiserum (direct antiglobulin test)
False positive and negative reactions may occur

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

AChR autoantibodies

Immune-mediated disease

A
Acquired MG (myasthenia gravis): most common of immune-mediated neuromuscular disorders
Various forms described: focal, generalised, acute fulminating, paraneoplastic
'Gold standard' for diagnosis of acquired MG is documentation of nicotinic AChR autoAb by immunoprecipitation RIA
False positives v rare; 2% of dogs with generalised MG may be seronegative
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

ANA - antinuclear antibodies

Immune-mediated disease

A

Serum ANA - hallmark of human, canine and feline SLE
Indirect immunofluorescence or immunoperoxidase test
Substrate tissues have inc. rat liver, vero and Hep-2 cells; various pattern of staining
False positives and negatives may occur

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Von Willebrand’s Factors (vWF)

A

Produced by endothelium and stored in Weibel Palade bodies
Also produced by platelets
Released early in the haemostatic process
Responsible for platelet adhesion to collagen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Platelets

A

Small discoid anuclear cells for in circulation
3-5 nanometres and are pale basophilic with small red granules
Derived from the cytoplasm of megakaryocytes in the bone marrow (thrombopoiesis)
Mediated by thrombopoietin
Circulate for 5-9 days in most species
Structure:
- Outer membrane contains receptors important for adhesion and aggregation
- Contain a cytoskeleton with actin and myosin that allows for shape change
- Contain membrane bound granules
Surface receptors:
- Glycoproteins associated with platelet membrane
- GP Ib - binds von Willebrand’s factor
- GP IIbIIa -binds fibrinogen on adjacent platelets and allows platelets to aggregate
- Defects in receptor lead to abnormal platelet function and clot formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Primary haemostasis

A

Damage to the endothelium and exposure of subendothelial collagen
Von Willebrand’s factor is released from damaged endothelium
Platelet adhesion occurs
Platelet bind to collagen via receptor GPIb and vWF from the endothelium
Once platelets have adhered to collagen, they undergo shape change and become spherical with filopodia
Additional receptors for vWF (GPIb) and fibrinogen (GPIIbIIa) are exposed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Secondary haemostasis

A

Involves activation of the coagulation cascade
Happens simultaneously with formation of the platelet plus because damage to the endothelium releases tissue factor and activates the extrinsic coagulation pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Coagulation cascade

Extrinsic system - intiation

A
Most important in vivo
Tissue factor (TF) released from damaged tissue binds and activates FVII in presence of calcium
TF_FVII complex activates FX of the common pathway and FIX of the intrinsic pathway
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Coagulation cascade

Intrinsic pathway - amplification

A

FXII is activated by contact with a negatively charged surface (cofactor HMWK)
Activated FXII cleaves and activates FXI which in turn activates FIX (calcium required)
Activated FIX i turn activates FX of the common pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Coagulation cascade | Common pathway
Starts with activation of Factor X Activated FX binds activated Factor V and calcium on the platelet surface This complex converts prothrombin (FII) to thrombin (FIIa) Thrombin converts fibrinogen (FI) to fibrin (FIa) Fibrin crosslinked by activated FXIII
26
Inhibitors of coagulation
Anti-thrombin III - inhibits thrombin and activated FX Activity of ATIII increased by heparin from the endothelium Protein C - inactivates Factors V and VIII Fibrinolysis (enzymatic breakdown of fibrin by plasmin)
27
Immune-mediated thrombocytopaenia
Most common cause of thrombocytopaenia Platelet numbers extremely low (often s syndome - concurrent immune mediated thrombocytopaenia and anaemia Primary - antibodies produced against platelets antigens Secondary - many causes (other immune diseases (SLE), drugs or vaccine, neoplasia, infectious) Diagnosis of exclusion/response to treatment
28
Disorders of platelet function
Glanzmann's thrombasthenia - defect in GPIIbIIIa - Ottermans and Great Pyrenees, Quarter horse - Defective platelet aggregation and abnormal clot retraction Canine thrombopathia - abnormal GPIIbIIIa exposure and impaired degranulation - Basset hounds Bovine thrombopathia - defect not know (Simmentals), mild to severe bleeding
29
Thrombocytosis
Physiological - transient - epinephrine induced splenic contraction Reactive (secondary) - Increased thrombopoietin and possibly IL6 - Inflammation, haemorrhage, iron deficiency Essential thrombocytemia - Myeloproliferative disorder - Marked peristent incerase in platelets - Bone marrow megakaryocytes increased and may have abnormal morphology - Function variable - may see petechiae and ecchymoses or thrombosis
30
Von Willebrand's disease
Clinical signs: mucosal bleeding (GI, epistaxis, haematuria etc.) Bleeding may be absent No petechiae - use to differentiate from other platelet disorders See prolonged buccal mucosal bleeding time without thrombocytopaenia Clotting time usually normal but PTT msy be prolonged due to decrease in factor VIII] Common in dogs (rare in cats and horses)
31
Von Willebrand's disease | Type I
All multimers are present but as decreased concentrations Variable severity of bleeding but not until concentration of vWF are <20% Most common - 90% cases Dobermans Autosomal inheritance so males and females equally affected
32
Von Willebrand's disease | Type II
Qualitative abnormalities in vWF structure and function Often disproportionate decrease in large multimers Severe and uncommon Seen in German short haired and wire haired pointers Autosomal recessive
33
Von Willebrand's disease | Type III
Absence of all vWF multimers (<0.1%) Seen in Scottish Terriers, Chesapeake Bay Retrievers, Shetland Sheepdogs and Dutch Kooiker Autosomal recessive
34
Von Willebrand's disease | Tests
Measure levels of vWF:Ag - Collect blood into EDTA or citrate - If using citrate as anticoagulation - dilute blood:citrate at ratio of 1:9 - vWF levels will be decreased by clots in the sample and by haemolysis but are inaffected by lipaemia - Separate plasma immmediately, freeze and ship overnight ELISA: quantative measurement of vWF using specific antibodies -<50% considered decreased Immunoelectrophoresis: used to separate relative amounts of different multimers - required for diagnosis of type II Genetic test to detect carriers
35
Von Willebrand's disease | Treatment
Transfusion to supply vWF Cryoprecipitate best - concentration of vWF 5-10x greater than in plasma - give at dose of 1 unit/10kg Plasma can be given at 6-12 ml/kg if cryoprecipitate nto available Whole blood if animal is anaemic Desmopressin (DDAVP)as a pre-op prophylaxis for dogs with type I vWD Causes release of vWF from endothelium Give dose of 1 nanog/kg SQ 30 min prior to surgery Intranasal preparation
36
Vitamin K deficiency
Factors II, VII, IX and X are produced in the liver Are activated by a vitamin K dependent carboxylase - this step requires reduced vitamin K Production of reduced vitamin K requires the action of vitamin K reductase Vitamin K reductase is inhibited by coumarin - type redenticides This leads to a lack of active factors II, VII, IX and X and a coagulopathy Extrinsic, intrinsic and common pathways affected Factor VII has the shortest half life so will decrease 1st PT is often prolonged 1st in early vitamin K deficency Main clinical sign: haemorrhage Test results: elevation in PT and PTT, platelet numbers and buccal mucosal bleeding time should be normal but mild thrombocytopaenia is possible - due to consumption associated with haemorrhage, FDP's may also be elevated
37
Vitamin K deficiency - Treatment
Emetics, cathartics, activated charcoal if ingestion of rodenticide is recent Transfusions of whole fresh blood or fresh frozen plasma to replace coagulation factors May also need packed red cells if severe anaemia is present Vitamin K therapy: - Can be given orally or parenterlly (SQ) - Loading dose of SQ and then lower dose 8h later - Same dose can be given orally with a fatty meal
38
Inherited coagulation defects - treatment Factor VII deficiency, Haemophilia A - factor VIII deficiency, Haemophilia B - factor IX deficiency, factor XI deficiency, Factor XII deficiency
Transfusions of whole blood or plasma to replace factor deficiency and red cells Use of fresh or frozen plasma will give a small amount of factor Administration of cryoprecipitate - 10x more factor VIII vs plasma
39
Disseminated intravascular coagulation (DIC)
Mixed haemostatic defect Results when excessive coagulation leads to widespread thrombosis Haemorrhage eventually results as all coagulation factors are consumed Not a primary event but secondary to other underlying disease (neoplasia, liver disease, immune mediated diseases, infectious diseases) May be chronic or acute Haemostatic abnormalities: thrombocytopaenia, prolonged PT and PTT, elevated FDP's, decrease fibrinogen, decreased antithrombin III
40
DIC - Treatment
``` Stop the coagulation process Heparin (different regimes) Transfusion of whole blood, plasma or cryoprecipitate as source of antithrombin III Aspirin to stop platelet activation Correct other underlying abnormalities Prognosis - poor ```
41
FeLV
Family Retroviridae, subfamily Oncovirinae, genus Gammaretrovirus Replicates in many tissues, non-cytopathic Prevalence of 1-2% in 'healthy' cats in UK, 20% in symptomatic cats Transmission: shed in saliva, nasal secretions, faeces, urine, milk, short survival outside of body - Intimate prolonged contact - Neonates (in utero, nursing) - Blood transfusions Persistent viraemia, transient viraemia, latent infection, localised infection
42
FeLV | Clinical signs
``` Inappetence Weight loss, wasting Poor coat condition Lymphadenopathy Persistent fever Pale mm Ocular disease Gingivitis Stomatitis Infections of skin, urinary bladder, upper resp tract Persistent diarrhoea Seizures, behavioural changes and other neuro disorders Queen's - abortions ```
43
FeLV | Secondary infections
Immunosuppression - most common manifestation of FeLV Depletion of interference with function of lymphocytes +/- neutrophils Susceptible to co-infection - common for FeLV+ cats to have concurrent infection (opportunistic pathogens)
44
FeLV | Haematological disorders
Bone marrow suppression: viral infection of haemopoietic stem cells and stromal cells - Anaemia: non-regenerative, aplastic anaemia, regenerative (10%) - Thrombocytopaenia - Granulocytopaenia Myelodysplasia -> myelodysplastic syndrome Leukaemia (all cell lines susceptible)
45
FeLV | Lymphoma
FeLV+ cats, >60x increased risk of lymphoma Expect to develop in 25% of FeLV+ cats within two years of diagnosis Most often mediastinal (thymic) and multicentric Some cats with lymphoma test FeLV- but have virus in tumours
46
FeLV | Diagnostic tests
Immunoassay - screening (ELISA) Immunofluorescent antibody test (IFA) - confirms Polymerase chain reaction (PCR) - confirms Viral culture - gold standard confirms Antibody tests - not for diagnosis
47
FeLV | Treatment
Systemically well: - General preventative helath care - Neuter and confine indoors Sick: - Supportive care - Treat secondary illness - Confine indoors
48
FIV
Family Retroviridae, genus Lentivirus, RNA virus, five subtypes - similar to HIV, not zoonotic Clinical findings: stomatitis, neoplasia, ocular inflammation (uveitis, chorioretinitis), anaemia and leucopaenia, opportunistic infections, renal insufficiency
49
FIV | Diagnosis
``` CBC: neutropaenia, anaemia common, thrombocytopaenia, co-infection with Mycoplasma haemofelis - haemolytic anaemia Serum biochemical profile: no particular abnorm, +/- polyclonal gammapathy Tests: - Antibody test - develop with 60d - IFA - detects antibodies - Western blot - confirms - PCR - Viral isolation ```
50
FIV | Treatment
``` Supportive therapy: - antibiotics (aerobes) - cautious use of glucocorticoids in combo with antibiotics (gingivitis, stomatitis) - lactoferrin - possibly in stomatitis Antiviral therapy: - Zidovudine - Reduce plasma load - Generally well tolerated but check for Heinz body haemolytic anaemia and non-regenerative anaemia ```
51
FIV | Prevention of infection
``` Prevent exposure to virus Virus readily killed but disinfectants, dies within a few hours in environment Low risk transmission by social contact Do not breed fro FIV+ queens If FIV+ queen, hand rear kittens ```
52
FeLV | Subgroups
Subgroup A: - present in almost all FeLV-infected cats - transmitted cat-cat - basis from production of other subgroup - least pathogenic Subgroup B: - recombination of subgroup A with endogenous FeLV proviral sequences - oncogenic Subgroup C: - arises from mutation of subgroup A - non-regenerative anaemia
53
FIP
Fatal disease, domestic and non-domestic cats Causative agent: feline coronavirus, enveloped, ssRNA virus Replicates in cytoplasm FIP in 5-10% of FCoV infections Vasculitis, complement activation, excessive cytokine formation Clinical signs: consequences of vasculitis and secondary organ damage Incubation period: weeks - months Onset: sudden or insidious
54
Feline enteric coronavirus (FECV)
Present in large portion of healthy cat population Oronasal transmission Virus replicates in enterocytes Clinical signs mild/inapparent - V and D, upper resp signs
55
Feline infectious peritonitis virus (FIPV)
FCoV may undergo mutations to FIPV Infects macrophages -> systemic infection FIP = clinical disease syndome result from ineffective immune reponse
56
FIP | Clinical signs
Early: - Pyrexia - Inappetence/anorexia, weight loss - Diarrhoea - Listlessness, dehydration - Jaundice (icterus) Effusive vs non-effusive form (sometimes mixed) - Effusive: abdominal, pleural, pericardial effusions - Non-effusive: dry or granulomatous form, predisposition to eye, brain and CNS, kidney, liver, localised regions of intestine
57
FIP | Diagnosis
Often difficult AM (esp dry form) CBC: Lymphopaenia, neutrophilia with mild left shift, mild non-regenerative anaemia, may also be normal Serum biochem: Hyperglbulinaemia (polyclonal increase in gamma globulins, albumin:globukin ratio <0.5) hyperbilirubinaemia, usually not azotaemic, may also be normal Fluid analysis: clear, straw - yellow colour, high protein content, viscous, cellularity variable
58
FIP | Treatment/prognosis
Grave prognosis - no cure usually, palliative treatment Options: - Suppotive/palliative care - Abx, SQ fluids, nutrition, rest, thoracocentesis - Immune modulators - Glucocorticoids +/- chlorambucil - Aspirin? - Oral polyprenyl immunostimulant
59
FIA (feline infectious anaemia)
Haematropic mycoplasmas: - Mycoplasma haemofelis: anaemia, pleiomorphic (rods, rings or spherical), gram negative, young entire males - Candidatus Mycoplasma haemominutum: - Candidatus Mycoplasms turicensis Pathogenesis: - Mycoplasmas attach to RBC -> immune-mediated destruction - Concurrent diseases, immunosuppression -> enhanced disease - If recover from infection -> chronic infection fro variable time
60
FIA | Transmission
Fleas Blood transfusion Female cats to neonates - in utero, nursing Fighting? Oral? Experimentally: IP, IV and PO infected blood, urine and saliva not thought to be infective
61
M. haemofelis | Clinical signs
Acute: lethargy, inappetence/anorexia, fever (39-41), anaemia, splenomegaly, icterus Chronic: normal to subnormal temperature, weakness, depression, weight loss/emaciation, icterus and splenomegaly less likely
62
M. haemofelis | CBC
Regenerative anaemia: varies in severity (PCV 15-18%), reticulocytosis, regenerative morphology, if acute onset may be pre-regenerative Erythrophagocytosis and autoagglutination may be present Leucocyte count variable: - Leucocytosis with monocytosis in acute forms - Normal counts in chronic forms - Leucopaenia in moribund cases
63
M. haemofelis | Treatment
Doxycycline: 5-10mg/kg orally bid for 14-21d Potentially adverse effects: GIT effects, abdominal discomfort, vomiting, inappetence/anorexia, oesophagitis, oesopharyngeal stricture formation Flea control Supportive care: blood transfusion, immunosuppresive therapy (pred)
64
M. haemofelis | Prognosis
No treatment - 1/3 with uncomplicated acute disease die | Regeneration - destruction + immune response to organism -> recovery
65
Clinical signs of farm animal anaemia
``` Pallor Lack of exercise intolerance Weakness Haemic murmur Red urine Jaundice Dependent oedema Black faeces Swollen udder ```
66
Causes of haemorrhagic anaemia | Farm animals
``` Caudal vena caval syndrome Enzootic haematuria Ruptured uterine artery Ruptured aorta Haemonchosis Fasciolosis Lice, mites and ticks Pyelonephritis Abomasal ulcer Intraluminal intestinal haemorrhage Gastric ulceration in pigs Proliferative haemorrhagic enteropathy in pigs (PIA) ```
67
Causes of haemolytic anaemic | Farm animals
``` Leptospirosis Postparturient haemoglobinuria Bacillary haemoglobinuria Protozoa (Babesia, Eperythrozoon) Chronic copper poisoning Cold water ingestion Brassica spp poisoning (rape, kale, cabbages) Drug induced Blood transfusion Autoimmune haemolytic anaemia ```
68
Depressed erythrocyte production | Farm animals
``` Deficiency of cobalt or copper Iron deficiency Acute bracken poisoning (enzootic haematuria) Faciolosis Lymphosarcoma Chronic renal disease (amyloidosis, pyelonephritis) Anaemia of inflammatory disease Radiation damage ```
69
Enzootic haematuria
Clinical signs: - Haematuria with blood clots - Freq urination - Thickened bladder may or may not be palpable per rectum - Other signs of chronic progressive anaemia - Internal bleedings Diagnosis: - Most common cause of haematuria in cattle - Pyelonephritis also causes haematuria but not necessarily anaemia
70
Abomasal ulcer
``` Sand, DA, 'stress' Diagnosis: - Occult blood in faeces/black stinking dung - Free air in the abdomen - Abdominal pain ```
71
Chronic copper poisoning | Farm animals
Species and breed variation in susceptibility Copper is stored and accumulated in the liver Some centrilobular necrosis occurs as liver copper concentrations rise Sudden release of copper from the liver - acute fatal syndrome develops
72
Chronic copper poisoning | Farm animals - Diagnosis
Clinical signs: jaundice, pallor, haemoglobinuria, depression, death (24-48h) Clinical path: Blood copper elevated, liver copper elevated, increased plasma AST Necopsy: swollen yellow liver, swollen gunmetal kidneys, jaundice everywhere
73
Chronic copper poisoning | Farm animals - Treatment
Treatment: - Ammonium tetrathiomolybdate (ATM) 2.7 mg/kg IV 2-3d intervals 3-6 treatments - Ammonium molybdate 100mg + sodium aulphate 1g oral daily - Sodium calcium edetate 70mg/kg IV 2d - Somnulose 10ml IV
74
Chronic copper poisoning | Farm animals - prevention
Dietary copper < 10 ppm Cu absorption inhibitors (Mo, Zn, Fe and soil) Avoid prolonged feeding of concentrates
75
Physiology of colostrum - calves
Starting 4-6 weeks before calving there is transfer of immunoglobulins (Ig) into the udder IgG1 is actively transferred into colostrum Following ingestion of colostrum by the calf, Ig is absorbed by the epithelial cells of the SI and passes via the lymphatic system to the peripheral blood circulation Systemic production in the calf by IgG and IgM Local protection of intestine by: 1. re-secretion of IgG into the gut lumen 2. passage of IgA in colostrum (and milk) through the gut lumen
76
Immune mediated haemolytic anaemia - Eqine
Primary - uncommon Secondary - antibodies attach to RBC membranes: - Alterations in RBC membrane produced by primary infectious, neoplastic or other immune-mediated disease process - Antigen-antibody complex deposition on RBC surface - Drugs that cause immunoproteins to react indirectly with RBCs
77
Oxidative damage to RBCs (Heinz body anaemia) | Equine
Heinz bodies are precipitations of oxidatively denatured haemoglobin on RBC membrane Can be caused by rarely used drugs (methylen blue, phenothiazine) or plants (onions, Brassica spp: rape, kale) Exception: red maple leaf toxicity
78
Equine infectious anaemia
Exotic, Equine infectious anaemia virus (lentivirus) | Persistent infection: no treatment, lifelong carriers
79
Anaemia of chronic disease | Equine
``` Most common cause Mild-moderatre regenerative anaemia Pathogenesis: - Iron sequestration - anti-bacterial mechanism - Defective erythropoietin - Decreased RBC lifespan ```
80
Failure of passive transfer - foal
Lack of colostrum/poor quality Failure to nurse Failure of absorption Measure IgG conc - <12-18h oral colostrum unless foal has system disease process - or IV plasma - 1l = 2g in blood (2l usually required) - Repeat measuring/transfusions as necessary
81
Neonatal isoerythrolysis - foals
Destruction of foal's RBC by antibodies present in colostrums directed against foal's RBC antigens Blood group incompatibility between mare and foal Clinical signs: - First 4d of life - Weakness, lethargy, increased hr and rr, icterus, pale mm Diagnosis on clinical signs and haemolytic cross match Treatment: - 24-48 hours - prevent further colostrum intake - Over that, supportive care - Blood transfusion: mare's washed red cells (not plasma) or typed donor
82
Sever combined immunodeficiency - horses
Arab foals - autosomal recessive inheritance Lack of functional T and B lymphocytes Fatal by several months of age Can test for SCID gene